<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676374</url>
  </required_header>
  <id_info>
    <org_study_id>S61035</org_study_id>
    <nct_id>NCT03676374</nct_id>
  </id_info>
  <brief_title>Prucalopride Treatment for Refractory Gastro-esophageal Reflux Disease</brief_title>
  <official_title>A Placebo-controlled Trial With Prucalopride for the Treatment of Typical Reflux Symptoms in Patients With Gastro-esophageal Reflux Disease With Incomplete Proton Pump Inhibitor Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to date there is no placebo-controlled trial to investigate the effect of prucalopride in&#xD;
      patients with proven refractory GERD. Therefore, to evaluate the efficacy of prucalopride on&#xD;
      the improvement in symptom severity and reflux parameters, we will conduct a randomized,&#xD;
      parallel, placebo-controlled, single-blind study. 60 patients with refractory GERD symptoms&#xD;
      will receive either placebo or prucalopride (Resolor®) 2 mg for a period of 4 weeks. Symptom&#xD;
      severity will be assessed by a validated reflux questionnaire (ReQuest) and reflux parameters&#xD;
      (acid exposure time and number of reflux episodes) will be assessed by means of a 24 hour&#xD;
      impedance-pH monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in acid exposure time</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in acid exposure time assessed by 24 hour impedance-pH monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in number of reflux episodes</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in number of reflux episodes assessed by 24 hour impedance-pH monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom severity</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in symptom severity assessed by a validated reflux questionnaire (ReQuest questionnaire and diaries)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prucalopride 2mg once a day as add-on for PPI 2x/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day as add-on for PPI 2x/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>Prucalopride 2mg taken once a day as add-on to PPI (2x/d)</description>
    <arm_group_label>Prucalopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablet taken once a day as add-on to PPI (2x/d)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 65 years old.&#xD;
&#xD;
          2. Patients must have proven reflux, documented either by the presence of esophagitis (≥&#xD;
             grade B) at upper endoscopy (&quot;on&quot; PPI b.i.d.) in the 24 months prior to inclusion or&#xD;
             pathological reflux parameters (acid exposure time &gt;4% or number of reflux episodes&#xD;
             &gt;40) on a 24 hour impedance-pH monitoring (&quot;on&quot; PPI b.i.d.) in the 6 months prior to&#xD;
             inclusion.&#xD;
&#xD;
          3. History of typical GERD symptoms during PPI treatment, at least 3 times per week for&#xD;
             12 weeks.&#xD;
&#xD;
          4. Daily intake of PPI treatment 12 weeks prior to inclusion, with at least 8 weeks of&#xD;
             b.i.d. therapy (at least 2*20mg of omeprazole or equivalent).&#xD;
&#xD;
          5. Sexually active women of child bearing potential participating in the study must use a&#xD;
             medically acceptable form of contraception. Medically acceptable forms of&#xD;
             contraception do not include oral contraceptives, due to expected diarrhea as side&#xD;
             effect of prucalopride. Injectable or implantable methods, intrauterine devices, or&#xD;
             properly used barrier contraception are acceptable forms of contraception.&#xD;
&#xD;
          6. Subjects must be capable of understanding and be willing to provide signed and dated&#xD;
             written voluntary informed consent before any protocol-specific screening procedures&#xD;
             are performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systemic diseases, known to affect esophageal motility.&#xD;
&#xD;
          2. Colitis ulcerosa, Crohn's disease, toxic megacolon.&#xD;
&#xD;
          3. Have a cardiovascular disease or QT c&gt;450 ms&#xD;
&#xD;
          4. Severely decreased kidney function.&#xD;
&#xD;
          5. Severely decreased liver function.&#xD;
&#xD;
          6. Surgery in the thorax or in the upper part of the abdomen (appendectomy and&#xD;
             cholecystectomy are allowed).&#xD;
&#xD;
          7. Number of stools &gt;3 per day.&#xD;
&#xD;
          8. Major psychiatric disorder.&#xD;
&#xD;
          9. Treatment with prucalopride prior to the start of the study.&#xD;
&#xD;
         10. Concomitant use of medications such as: anticholinergics, baclofen or prokinetics.&#xD;
&#xD;
         11. Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular,&#xD;
             metabolic or gastrointestinal cerebrovascular disease as judged by the investigator.&#xD;
&#xD;
         12. Absence of PPI intake for at least 2 consecutive days in the 2 weeks prior to the&#xD;
             screening.&#xD;
&#xD;
         13. Pregnancy or breast feeding.&#xD;
&#xD;
         14. History of poor compliance. History of/or current psychiatric illness that would&#xD;
             interfere with ability to comply with protocol requirements or give informed consent.&#xD;
&#xD;
         15. History of alcohol or drug abuse that would interfere with ability to comply with&#xD;
             protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hannelore Geysen</last_name>
    <phone>+32 (0)16 324921</phone>
    <email>hannelore.geysen@kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannelore Geysen</last_name>
      <phone>+32 (0)16 324921</phone>
      <email>hannelore.geysen@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Jan Tack</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

